SOURCE: Wall Street Equity Research

Wall Street Equity Research

November 23, 2010 08:38 ET

Professional Research on Mylan Inc. and Watson Pharmaceuticals Inc. - Generic Drug Manufacturers Post Mixed Results on Court Rulings

JOHANNESBURG, SOUTH AFRICA--(Marketwire - November 23, 2010) - allows shareholders to gain full understanding of the economic and market forces influencing the drugs-generic industry, and offers free research on industry players Mylan Inc. (NASDAQ: MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI). Register today at to receive free research reports on these companies.

Generic drug manufacturers have done fairly well in the third quarter, as patent expiration and a tight economy have seen more people opting for generic alternatives. Potential buyout possibilities have also helped drive up stock prices in some cases; however, court rulings remain the focus in the industry. is a specialized website where investors can have complete access to free reports on drugs-generic industry; traders looking for analyst opinions on Mylan Inc., Watson Pharmaceuticals Inc. and other players in the industry are welcomed to sign up for a free one year membership at

Generic drug makers live and die by court rulings that either allow them to produce generic alternatives or block them from doing so. Companies in the industry have had mixed success in this regard, as lawsuits have gone both ways. Visit us at to understand the catalysts and forces driving or affecting drugs-generic stocks.

Mylan Inc. has won production and distribution rights for their generic sleep disorder drugs in the U.K. which has helped to drive up profits. While this bodes well, there are also pending lawsuits filed by brand name drug manufacturers and the U.S. Government against this generic producer. The lawsuits are designed to stop Mylan from making their own versions of HIV medications. Shareholders and investors can sign up today at to download the full report on Mylan Inc.

Some companies such as Watson Pharmaceuticals Inc. have also been on the receiving end of drug pricing lawsuits. With the settlements and implications of court rulings translating into tens if not hundreds of millions of dollars, positive court rulings are paramount for success. Shareholders and investors can sign up today at to download the full report on Watson Pharmaceuticals Inc.

About Wall Street Equity Research: 
Wall Street Equity Research looks to bring simplicity and highly sophisticated research to an ever-changing investing environment. Wall Street Equity Research has been partnering with a number of North American and Emerging Economies analysts to bring you the best of both continents in terms of market analysis and analytical opinions. 

Contact Information